[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricular-thrombus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricular-thrombus":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,68,95,123,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100507796","anti-coagulation-on-left-ventricular-thrombus-after-st-segment-elevation-myocardial-infarction-100507796",false,"NCT05892042","Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction","Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction","ACTonLVT","Inclusion Criteria:\n\nEstablished ST segment elevation myocardial infarction within 7 days Left ventricular thrombus (LVT) is detected by either cardiac magnetic resonance (CMR) or TTE.\n\nOngoing treatment with dual anti-platelet therapy according to ESC\u002FAHA guidelines at the time of randomization\n\nExclusion Criteria:\n\nClinically or hemodynamically unstable planed major surgeon such as CABG or Valve replacement within next 12 months Concomitant condition that requires anti- coagulation therapy, such as AF, DVT.\n\nAny contraindication of anticoagulant therapy History of intracranial hemorrhage; Woman who is currently pregnant, or breastfeeding serious impaired renal and liver functions life expectancy less than 1 year can not provide consent","ALL","18 Years","80 Years",{"count":21,"type":22},320,"ESTIMATED","INTERVENTIONAL",[25],"NA","Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction",[28,29],"ST-segment Elevation Myocardial Infarction (STEMI)","Left Ventricular Thrombus",[31],"STEMI, LVT, Anticoagulation","RECRUITING","2026-05-27",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":36},"2023-05-01",{"date":40,"type":22},"2026-12-01",{"name":42,"class":43},"Jilin University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100590142","left-ventricular-thrombus-registry-100590142","NCT06963567","Left Ventricular Thrombus Registry","Observational Registry to Determine the Predictors and Outcomes of Patients at Risk of and Diagnosed With Left Ventricular Thrombus","LVT Registry","Inclusion Criteria:\n\n* Patients with LV thrombus or;\n* Patients at risk for developing LV thrombus (e.g severe LV dysfunction, LV aneurysm, MI.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Unable to consent",true,{"count":55,"type":22},1500,"OBSERVATIONAL","Left Ventricular Thrombus (LVT) is a blood clot that can develop in a poorly functioning heart. In around 1 in 6 patients who have had a heart attack or diagnosed with heart failure tend to develop blood clots in their main heart chamber.\n\nHaving a blot clot in the main heart chamber can lead to serious complications such as stroke. Treatment for blood clots is blood thinning medications, which if taken for a prolonged period of time can result in bleeding which further complicates treatment. We hope to gather information to better understand the factors associated with blood clot formation and management in the lower left chamber of the heart. This understanding will hopefully enable us and others to improve management of this condition in the future and therefore help the wider population. As part of this study, bloods and scan results will be recorded and we will complete a short quality of life questionnaire. When participants come in for routine MRI scan, we may capture additional images for further research analysis.\n\nA sample of blood no more than one tablespoon will be collected for research analysis at the same time as routine blood test. This will occur at baseline and at around 6 months. At 12 months we will repeat the quality of life questionnaire and collect final data.",[29],"2026-05-05",{"date":61,"type":36},"2026-05-06",{"date":63,"type":36},"2024-05-17",{"date":65,"type":22},"2027-01-31",{"name":67,"class":43},"Queen Mary University of London",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100611855","phase-2-lvt-duration-pilot-study-of-anticoagulation-duration-for-left-ventricular-thrombus-100611855","NCT07246005","LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus","A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus","LVT Duration","Inclusion Criteria:\n\n* Diagnosis of LV thrombus less than 12 months ago\n* On Apixaban at the time of randomisation\n* Completed at least 3 months of anticoagulation treatment for LV thrombus\n* Persistent laminar\u002F mural thrombus or persistent LV dysfunction\n\nExclusion Criteria:\n\n* Any clinical condition requiring long term anticoagulation treatment as per investigator's judgement.\n* SSE since LV thrombus diagnosis\n* Contraindication to continuing anticoagulation therapy\n* Non-ischaemic Cardiomyopathy\n* Age less than 18 years\n* Unable to consent",{"count":77,"type":22},120,[79],"PHASE2","The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:\n\n* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.\n* To identify the optimal length of anticoagulation in the treatment of LV Thrombus\n\nAfter randomisation participants will:\n\n* Continue their prescribed oral anticoagulant for the remainder of the trial\n* Discontinue their prescribed oral anticoagulant for the remainder of the trial",[29],[83,29,84,85,86],"LVT","Thrombus","Thrombi","anticoagulant","NOT_YET_RECRUITING","2026-02-26",{"date":90,"type":36},"2026-02-27",{"date":40,"type":22},{"date":93,"type":22},"2027-12-01",{"name":67,"class":43},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100555718","phase-4-treatment-with-apixaban-versus-warfarin-in-patients-with-left-ventricular-thrombus-after-acute-myocardial-infarction-100555718","NCT06515730","Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","RandomizEd compariSOn of Apixaban Versus Warfarin in Patients With Left VEntricular Thrombus After Acute Myocardial Infarction (RESOLVE-AMI)","RESOLVE-AMI","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of signing the informed consent\n* LV thrombus confirmed on TTE\\* day 1-28 after the AMI\n* Signed informed consent\n* Criteria applicable only for female subjects: Women of childbearing potential must provide a negative pregnancy test not be breastfeeding and be willing and able to use highly effective contraception. Women of non-childbearing potential must be 1 year post-menopausal.\n\nExclusion Criteria:\n\n* Ongoing\\* treatment with anticoagulant therapy due to Mechanical heart valve prosthesis Atrial fibrillation with or without significant mitral valve stenosis Venous thromboembolism requiring anticoagulant therapy Thrombophilia requiring anticoagulant therapy Preexisting LV thrombus already treated with anticoagulant therapy Other reasons for anticoagulant therapy\n* High bleeding risk Active non-trivial bleeding Known chronic bleeding disorder Severe anemia defined as hemoglobin \\\u003C 80g\u002FL Thrombocytopenia defined as platelet count \\\u003C 80 x 10\\^9\n* Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or known hepatic insufficiency classified as Child-Pugh C or D at randomization\n* Known allergy, intolerance or hypersensitivity to either of the study interventions\n* Any contraindication for the use of an anticoagulant or listed in the local labelling for apixaban or warfarin.\n* Participation in other study investigating effects and safety of anticoagulant treatment.\n* Known current alcohol or drug abuse\n* Any other condition, as judged by the investigator, that would make the participant unsafe or unsuitable for the study or life expectancy \\\u003C 6 months",{"count":104,"type":22},212,[106],"PHASE4","The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.",[29,109],"Acute Myocardial Infarction",[111,112],"Apixaban","warfarin","2025-06-26",{"date":115,"type":36},"2025-07-01",{"date":117,"type":36},"2025-04-08",{"date":119,"type":22},"2028-07-01",{"name":121,"class":43},"Karolinska Institutet",16,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":44},"100500295","phase-4-anticoagulation-in-post-mi-lv-thrombus-trial-in-nepal-100500295","NCT05794399","Anticoagulation in Post MI LV Thrombus Trial in Nepal","Comparison of Warfarin Versus Rivaroxaban in Management of Post-myocardial Infarction Left Ventricular Thrombus in a Tertiary Cardiac Center of Nepal: a Randomized Control Study.","WaRMIN","Inclusion Criteria:\n\n* Patients aged \\>18 years hospitalized with the diagnosis of acute STEMI and\n* Presence of LV thrombus which is confirmed with cardiac MRI.\n\nExclusion Criteria:\n\n1. Bleeding risk Active bleeding; history of intracranial hemorrhage; clinically significant gastrointestinal bleeding within 12 months before randomization; severe thrombocytopenia (\\\u003C50×109\u002FL), or anemia (i.e., hemoglobin \\\u003C90 g\u002FL) at screening or pre-randomization; Liver function Child-Pugh B or C; untreated arterial aneurysm, arterial or venous malformation and aorta dissection; and body weight \\\u003C40 kg.\n2. Undergoing anticoagulation therapy\n3. Cardiovascular condition Cardiac shock; uncontrolled blood pressure (SBP ≥180 mmHg); planned CABG within 3 months; suspicious Pseudo-ventricular aneurysm\n4. Concomitant diseases Severe chronic or acute renal failure (CrCl \\\u003C50 mL\u002Fmin at screening or pre-randomization); significant liver disease; current substance abuse (drug or alcohol) problem; life expectancy to less than 12 months; Known allergies, or intolerance to rivaroxaban; Woman who is currently pregnant, or breastfeeding; and Other hypercoagulable states, such as a malignant tumor, SLE\n5. Other conditions adjudicated by investigators to be unsuitable for anticoagulation\n6. Pregnant women and participants with any cognitive impairment.",{"count":132,"type":22},196,[106],"Introduction:\n\nThe prevalence of left ventricular(LV) thrombus after acute myocardial infarction has decreased with thrombolysis and primary angioplasty intervention worldwide. However, most of the patients in our country present late after the onset of ischemia resulting in a comparable increase proportion of late presentation MI compared to developed countries. This delayed presentation is associated with the increased incidence of LV thrombus, associated with increased cerebrovascular and cardiovascular events resulting in increased morbidity and mortality. The Vitamin K Antagonist Warfarin is indicated in recent guidelines for the duration of 3-6 months. The use of Warfarin is less in our part of the world due to the requirement of frequent International Normalized Ration (INR) monitoring and dietary restrictions. Novel oral anticoagulants (NOACs) are an alternate option for such hindrance to the treatment of LV thrombus. This research will help assess the safety and efficacy of Rivaroxaban, one of the NOACs compared to warfarin.\n\nObjectives:\n\nOur aim will be to compare the efficacy of rivaroxaban compared to warfarin in the complete resolution of post-MI LV thrombus. The primary efficacy endpoint of our study will be a resolution of LV thrombus as assessed by cardiac MRI at the end of 3 months of the study period. The secondary endpoint will be the comparison of the safety of both drugs measured by the incidence of major bleeding and embolic events.\n\nMethods:\n\nThe patients who present late after acute MI in our center with LV thrombus will be enrolled in our study. The diagnosis of LV thrombus will be diagnosed by cardiac MRI, which is considered the gold standard for the diagnosis. The patients then will be randomized in a 1:1 ratio to either warfarin or rivaroxaban within 24 hours of diagnosis of LV thrombus. The warfarin group will be prescribed the warfarin in the dose of 5mg daily and the dose titrated according to the INR value to maintain the INR range of 2 to 3. Rivaroxaban group will be prescribed 15 to 20mg according to the indication. The research group consisting of the principal investigator and coinvestigators will be responsible for the recruitment and overall study procedures.",[29,136],"Myocardial Infarction",[138,29,139,140,141],"Post Myocardial Infarction","Warfarin","Rivaroxaban","Nepal","2025-05-06",{"date":144,"type":36},"2025-05-11",{"date":146,"type":36},"2023-06-19",{"date":148,"type":22},"2026-04",{"name":150,"class":43},"Shahid Gangalal National Heart Centre",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":44},"100573152","phase-3-apixaban-prophylaxis-for-prevention-of-left-ventricular-thrombus-following-anterior-myocardial-infarction-100573152","NCT06742567","Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction: An Open Label, Randomized Clinical Trial (POTAMI)","POTAMI","Inclusion Criteria:\n\n* Patients aged 18-65 years\n* Presenting with acute anterior STEMI\n* Severe LV dysfunction (EF\\\u003C35%) with antero-apical akinesis, dyskinesis, or aneurysm\n* WIHTOUT evidence of LV thrombus.\n\nExclusion Criteria:\n\n* Patients with previous anterior myocardial infarction or LAD revascularization procedures\n* Patients with cardiogenic shock\n* Patients with LV thrombus\n* Patients with advanced CKD (Cr \\> 2 and those on hemodialysis)\n* Recent ICH or major bleed requiring transfusion, low platelet counts \\\u003C100,000\n* History of recent CVA ( within past three months)\n* Patients with atrial fibrillation or other indications for chronic anticoagulation\n* Pregnant patients and those with hematological disorders","75 Years",{"count":161,"type":22},472,[163],"PHASE3","The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.",[166,29,167],"Acute Myocardial Infarction of Anterior Wall","Prophylaxis",[169,170,171,172,173],"Acute myocardial infarction","severe left ventricular dysfunction","prevention of LV thrombus","DOAC","apixaban","2024-12-17",{"date":176,"type":36},"2024-12-19",{"date":178,"type":36},"2024-12-02",{"date":180,"type":22},"2025-11-30",{"name":182,"class":43},"National Institute of Cardiovascular Diseases, Pakistan"]